This immunotoxin was achieved by conjugating/fusing the Anti-Msln monoclonal antibody to Pseudomonas exotoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to cells expressed the cells surface antigen MSLN. Once bind, the toxin enters cells by receptor-mediated endocytosis. Then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis. It was designed for treating cancers; autoimmune diseases; lysosomal storage diseases; hemophilia; multiple sclerosis and transplant rejection.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.